AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Nurix Therapeutics Inc (NASDAQ:NRIX)
13.07 USD
+0.570 4.560%Sponsored Reports
Loading...
| Previous Close (in USD) | 12.5 |
|---|---|
| Change | +0.570 4.560% |
| 52 W H/L (in USD) | 18.120/4.220 |
| EBITDA (in USD) | -150.904M |
| PE Ratio | -- |
| Volume | 349660 |
| Diluted Eps TTM | -2.72 |
| Total Assets (in USD) | 364.539M |
|---|---|
| Total Liabilities (in USD) | 164.046M |
| Revenue TTM (in USD) | 80.887M |
| Cash (in USD) | 54.627M |
| Market Cap (in USD) | 948.989 M |
| Revenue Per Share TTM | 1.483 |
| Gross Profit TTM (in USD) | -145.87M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Nurix Therapeutics Inc
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Employees: 284
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Arthur T. Sands M.D., Ph.D. | CEO, Pres & Director | 1962 |
| 2. | Mr. Johannes Van Houte | Chief Financial Officer | 1966 |
| 3. | Ms. Stefani A. Wolff | COO & Exec. VP of Product Devel. | 1962 |
| 4. | Dr. Gwenn M. Hansen Ph.D. | Chief Scientific Officer | 1971 |
| 5. | Dr. Christine Ring | Gen. Counsel & Sec. | 1965 |
| 6. | Dr. John Kuriyan Ph.D. | Founder & Member of Scientific Advisory Board | NA |
| 7. | Dr. Michael Rapé Ph.D. | Founder & Member of Scientific Advisory Board | NA |
| 8. | Prof. Arthur Weiss M.D., Ph.D. | Founder & Member of Scientific Advisory Board | NA |
| 9. | Mr. Howard A. Simon J.D., Esq., SPHR | VP of Operations & Corp. Counsel | 1959 |
| 10. | Rita Kwong | Sr. Accounting Mang. | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 30-11-2022 | 30-11-2021 | 30-11-2020 | 30-11-2019 | 30-11-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -180.36M | -117.063M | -63.777M | -21.46M | -8.921M |
| Minority Interest | - | - | - | - | - |
| Net Income | -166.045M | -117.194M | -43.242M | -21.699M | -9.428M |
| Selling General Administrative | 37.997M | 31.202M | 16.309M | 8.326M | 6.674M |
| Gross Profit | 38.627M | 29.75M | 17.82M | 31.115M | 37.449M |
| Reconciled Depreciation | 10.808M | 6.082M | 2.18M | 2.354M | 2.988M |
| Ebit | -194.675M | -123.968M | -67.163M | -22.236M | -9.739M |
| Ebitda | -183.867M | -117.886M | -64.983M | -19.882M | -6.751M |
| Depreciation And Amortization | 10.808M | 6.082M | 2.18M | 2.354M | 2.988M |
| Operating Income | -183.867M | -117.886M | -64.983M | -22.236M | -9.739M |
| Other Operating Expenses | 222.494M | 147.636M | 82.803M | 53.351M | 47.188M |
| Interest Expense | -14.315M | 6.905M | 3.386M | 0.776M | 0.818M |
| Tax Provision | 0M | 0.131M | -20.535M | 0.239M | 0.507M |
| Interest Income | 3.507M | 0.823M | 1.206M | 0.776M | 0.818M |
| Net Interest Income | 3.507M | 0.823M | 1.206M | 0.776M | 0.818M |
| Income Tax Expense | -14.315M | 0.131M | -20.535M | 0.239M | 0.507M |
| Total Revenue | 38.627M | 29.75M | 17.82M | 31.115M | 37.449M |
| Total Operating Expenses | 222.494M | 147.636M | 82.803M | 53.351M | 47.188M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 3.507M | 0.823M | 1.206M | 0.776M | 0.818M |
| Net Income From Continuing Ops | -180.36M | -117.194M | -43.242M | -21.699M | -9.428M |
| Net Income Applicable To Common Shares | -180.36M | -117.194M | -43.242M | -21.699M | -9.428M |
Balance Sheet
(Currency in USD)| Breakdown | 30-11-2023 | 30-11-2022 | 30-11-2021 | 30-11-2020 | 30-11-2019 |
|---|---|---|---|---|---|
| Total Assets | 364.539M | 416.759M | 476.771M | 396.343M | 44.048M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.795M | 9.308M | 9.194M | 5.94M | 1.634M |
| Total Liab | 164.046M | 113.063M | 134.469M | 106.074M | 101.762M |
| Total Stockholder Equity | 200.493M | 303.696M | 342.302M | 290.269M | -57.714M |
| Other Current Liab | 24.97M | 22.428M | 14.549M | 0.7M | 0.309M |
| Common Stock | 0.049M | 0.047M | 0.045M | 0.039M | 0.004M |
| Capital Stock | 0.049M | 0.047M | 0.045M | 0.039M | 0.004M |
| Retained Earnings | -545.2M | -401.252M | -220.892M | -103.698M | -60.456M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 4.923M | 3.119M | 91.237M | 0.317M |
| Cash | 54.627M | 64.474M | 80.506M | 119.356M | 34.816M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 86.958M | 70.655M | 66.258M | 44.539M | 16.137M |
| Current Deferred Revenue | 48.098M | 37.633M | 41.212M | 32.799M | 9.612M |
| Net Debt | -24.013M | -52.51M | -67.47M | -119.356M | -34.816M |
| Short Term Debt | 7.489M | 5.53M | 3.847M | 7.628M | 4.618M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 30.614M | 11.964M | 13.036M | - | - |
| Other Stockholder Equity | 746.299M | 709.22M | 563.757M | -2.502M | 2.74M |
| Property Plant Equipment | - | 17.163M | 25.345M | 6.672M | 3.871M |
| Total Current Assets | 295.503M | 318.449M | 311.118M | 298.434M | 39.354M |
| Long Term Investments | 7.421M | 63.879M | 137.189M | 90.89M | 0.506M |
| Short Term Investments | 233.281M | 244.667M | 215.214M | 161.792M | 2.904M |
| Net Receivables | 0.8M | 1.1M | 6.204M | 11.346M | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 6.401M | 5.064M | 6.65M | 3.412M | 1.598M |
| Accumulated Other Comprehensive Income | -0.655M | -4.319M | -0.608M | 0.087M | -0.002M |
| Non Currrent Assets Other | 3.823M | 4.923M | 3.119M | 0.347M | 0.317M |
| Non Current Assets Total | 69.036M | 98.31M | 165.653M | 97.909M | 4.694M |
| Capital Lease Obligations | 30.614M | 11.964M | 13.036M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 30-11-2022 | 30-11-2021 | 30-11-2020 | 30-11-2019 | 30-11-2018 |
|---|---|---|---|---|---|
| Investments | 39.442M | -102.59M | -254.404M | 8.498M | 39.994M |
| Total Cashflows From Investing Activities | 27.198M | -108.251M | -254.404M | 8.498M | 39.994M |
| Total Cash From Financing Activities | 117.192M | 153.882M | 339.024M | 0.126M | 0.529M |
| Net Income | -180.36M | -117.194M | -43.242M | -21.699M | -9.428M |
| Change In Cash | -15.417M | -38.734M | 84.54M | 9.225M | 8.848M |
| Begin Period Cash Flow | 80.792M | 119.526M | 34.986M | 25.761M | 16.913M |
| End Period Cash Flow | 65.375M | 80.792M | 119.526M | 34.986M | 25.761M |
| Total Cash From Operating Activities | -159.807M | -84.365M | -0.08M | 0.601M | -31.675M |
| Depreciation | 10.808M | 6.082M | 2.18M | 2.354M | 2.988M |
| Other Cashflows From Investing Activities | - | - | - | 10.149M | 41.589M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 6.774M | - | - | - |
| Sale Purchase Of Stock | 117.192M | 153.883M | 219.117M | 0.126M | 0.529M |
| Other Cashflows From Financing Activities | 97.792M | 3.725M | 120.877M | 0.126M | 0.529M |
| Capital Expenditures | 12.244M | 5.661M | 4.553M | 1.651M | 1.595M |
| Change In Working Capital | -19.022M | 9.113M | 36.408M | 19.545M | -25.306M |
| Other Non Cash Items | 0.636M | 1.834M | 0.273M | -0.109M | -0.006M |
| Free Cash Flow | -172.051M | -90.026M | -4.633M | -1.05M | -33.27M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | ARK Genomic Revolution ETF | 1 year ago | 2635722 |
| 2. | ARK Genomic Revolution | 1 year ago | 2610055 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 1863179 |
| 4. | SPDR® S&P Biotech ETF | 1 year ago | 1641705 |
| 5. | US Small-Cap Growth II Equity Comp | 1 year ago | 1140710 |
| 6. | T. Rowe Price New Horizons | 1 year ago | 1140710 |
| 7. | iShares Russell 2000 ETF | 1 year ago | 1105886 |
| 8. | Wasatch Ultra Growth | 1 year ago | 872052 |
| 9. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 814877 |
| 10. | BlackRock Health Sciences Opps Inv A | 1 year ago | 619557 |
| 11. | Belfius Equities Cure C Cap | 1 year ago | 577096 |
| 12. | Xtrackers MSCI World Swap ETF 1C | 1 year ago | 537680 |
| 13. | Candriam Global Equities Oncology | 1 year ago | 537096 |
| 14. | Fidelity Small Cap Index | 1 year ago | 488349 |
| 15. | Xtrackers S&P Global Infra Swap ETF 1C | 1 year ago | 483688 |
| 16. | iShares Russell 2000 Value ETF | 1 year ago | 442269 |
| 17. | Pictet-Biotech P USD | 1 year ago | 409437 |
| 18. | BlackRock Health Sciences Term Trust | 1 year ago | 387016 |
| 19. | Candriam Eqs L Biotech C USD Cap | 1 year ago | 354992 |
| 20. | iShares Biotechnology ETF | 1 year ago | 335147 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 4643736 |
| 2. | Redmile Group, LLC | 1 year ago | 4483016 |
| 3. | Baker Bros Advisors LP | 1 year ago | 3882125 |
| 4. | Morgan Stanley - Brokerage Accounts | 1 year ago | 3135037 |
| 5. | Deep Track Capital, LP | 1 year ago | 2997830 |
| 6. | ARK Investment Management LLC | 1 year ago | 2635338 |
| 7. | Vanguard Group Inc | 1 year ago | 2584300 |
| 8. | T. Rowe Price Associates, Inc. | 1 year ago | 2196169 |
| 9. | Wasatch Advisors LP | 1 year ago | 1236753 |
| 10. | Bain Capital Life Sciences Investors, LLC | 1 year ago | 1132397 |
| 11. | Geode Capital Management, LLC | 1 year ago | 1080523 |
| 12. | Dimensional Fund Advisors, Inc. | 1 year ago | 966453 |
| 13. | State Street Corporation | 1 year ago | 921322 |
| 14. | Candriam Luxembourg S.C.A. | 1 year ago | 892110 |
| 15. | Pictet Asset Manangement SA | 1 year ago | 726941 |
| 16. | TCG Crossover Management, LLC | 1 year ago | 717654 |
| 17. | Affinity Asset Advisors, LLC | 1 year ago | 690112 |
| 18. | Charles Schwab Investment Management Inc | 1 year ago | 642190 |
| 19. | Goldman Sachs Group Inc | 1 year ago | 563800 |
| 20. | Nuveen Asset Management, LLC | 1 year ago | 533865 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...